Results 81 to 90 of about 482,699 (357)

CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma

Journal for ImmunoTherapy of Cancer, 2019
Despite remarkable success in the treatment of hematological malignancies, CAR T-cell therapies for solid tumors have floundered, in large part due to local immune suppression and the effects of prolonged stimulation leading to T-cell dysfunction and ...
Bryan D. Choi, Xiaoling Yu, Ana P. Castano, Henia Darr, Daniel B. Henderson, Amanda A. Bouffard, Rebecca C. Larson, Irene Scarfò, Stefanie R. Bailey, Genevieve M. Gerhard, Matthew J. Frigault, Mark B. Leick, Andrea Schmidts, Jason G. Sagert, William T. Curry, Bob S. Carter, Marcela V. Maus   +16 more
doaj   +1 more source

Probabilistically Certified Region of Attraction of a Tumor Growth Model with Combined Chemo- and Immunotherapy [PDF]

arXiv, 2020
This paper deals with the estimation of regions of attraction (RoAs) under parametric uncertainties for a cancer growth model with combined therapies. We propose a framework of probabilistic certification, based on the randomized methods, in order to derive probabilistically certified RoAs of a cancer growth model.
arxiv  

Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program [PDF]

, 2019
Background: The Italian Renal Cell Cancer Early Access Program was an expanded access program that allowed access to nivolumab, for patients (pts) with metastatic renal cell carcinoma (mRCC) prior to regulatory approval.
Buti, S, Cappuzzo, F, Cartenì, G, Cognetti, F, Cortesi, E, De Giglio, A, De Giorgi, U, Giannarelli, D, Panni, S, Pazzola, A, Porta, C, Procopio, G, Raimondi, A, Rastelli, F, Rossetti, S, Sabbatini, R, Sobrero, A, Sternberg, Cn, Surico, G, Tassinari, D, Tortora, G, Turci, D, Verzoni, E   +22 more
core   +3 more sources

Detection rate for ESR1 mutations is higher in circulating‐tumor‐cell‐derived genomic DNA than in paired plasma cell‐free DNA samples as revealed by ddPCR

Molecular Oncology, EarlyView.
Analysis of ESR1 mutations in plasma cell‐free DNA (cfDNA) is highly important for the selection of treatment in patients with breast cancer. Using multiplex‐ddPCR and identical blood draws, we investigated whether circulating tumor cells (CTCs) and cfDNA provide similar or complementary information for ESR1 mutations.
Stavroula Smilkou, Aliki Ntzifa, Victoria Tserpeli, Ioanna Balgkouranidou, Alkistis Papatheodoridi, Evangelia Razis, Helena Linardou, Christos Papadimitriou, Amanda Psyrri, Flora Zagouri, Stylianos Kakolyris, Evi Lianidou   +11 more
wiley   +1 more source

Phase I/II Clinical Study of PRaG Regimen Combined With Intraperitoneal Infusion of PD-1 Inhibitor for Advanced Refractory Solid Tumors With Cancerous Ascites (PRaG4.0P Study)

Technology in Cancer Research & Treatment
Objective: The prognosis of malignant tumors with peritoneal metastases and cancerous ascites has generally been poor, with limited treatment options.
Yingying Xu MS, Yuehong Kong MS, Yifu Ma MS, Meiling Xu MS, Jiabao Yang MS, Junjun Zhang PhD, Rongzheng Chen MS, Guangqiang Chen MS, Zhihui Hong MS, Xiangrong Zhao MS, Chenyang Zhang MS, Pengfei Xing MS, Liyuan Zhang MD, Peifeng Zhao MS   +13 more
doaj   +1 more source

DeepTCR is a deep learning framework for revealing sequence concepts within T-cell repertoires

Nature Communications, 2021
The advent of high-throughput T-cell receptor sequencing has allowed for the rapid and thorough characterization of the adaptive immune response. Here the authors show how deep learning can reveal both descriptive and predictive sequence concepts within ...
John-William Sidhom, H. Benjamin Larman, Drew M. Pardoll, Alexander S. Baras   +3 more
doaj   +1 more source

Exploring The Contribution of Innate Immune Cells to Breast Cancer Immunotherapy [PDF]

arXiv, 2023
Breast cancer is the leading type of cancer in women. About 10-15% of breast cancers are triple-negative breast cancer (TNBC), a subtype with the worst prognosis. Due to the lack of estrogen, progesterone and HER2 receptor expression, chemotherapies have been the standard of care for decades.
arxiv  

HDAC inhibition potentiates immunotherapy in triple negative breast cancer. [PDF]

, 2017
Triple-negative breast cancer (TNBC) represents a more aggressive and difficult subtype of breast cancer where responses to chemotherapy occur, but toxicity is significant and resistance often follows. Immunotherapy has shown promising results in various
Ali, Niwa, Budillon, Alfredo, Krings, Gregor, Munster, Pamela N, Park, Jeenah, Pawlowska, Nela, Rosenblum, Michael D, Terranova-Barberio, Manuela, Thomas, Scott   +8 more
core   +1 more source

Polyfunctional CD8+CD226+RUNX2hi effector T cells are diminished in advanced stages of chronic lymphocytic leukemia

Molecular Oncology, EarlyView.
CD226+CD8+ T cells express elevated levels of RUNX2, exhibit higher proliferation capacity, cytokines and cytolytic molecules expression, and migratory capacity. In contrast, CD226−CD8+ T cells display an exhausted phenotype associated with the increased expression of co‐inhibitory receptors and impaired effector functions.
Maryam Rezaeifar, Shima Shahbaz, Anthea C. Peters, Spencer B. Gibson, Shokrollah Elahi   +4 more
wiley   +1 more source

Clonal selection in the human Vδ1 T cell repertoire indicates γδ TCR-dependent adaptive immune surveillance

Nature Communications, 2017
γδ T cells are generally considered innate‐like lymphocytes. Here the authors sequence human γδ T cell receptors (TCR) to show focusing of the private Vδ1 TCR repertoire, suggesting that, unlike Vδ2 T cells, the Vδ1 T cell compartment has adaptive ...
Martin S. Davey, Carrie R. Willcox, Stephen P. Joyce, Kristin Ladell, Sofya A. Kasatskaya, James E. McLaren, Stuart Hunter, Mahboob Salim, Fiyaz Mohammed, David A. Price, Dmitriy M. Chudakov, Benjamin E. Willcox   +11 more
doaj   +1 more source